MinorMucolytic agent×Selective serotonin reuptake inhibitors
Updated · Methodology
Mechanism
Fluoxetine is metabolised in the liver mainly by CYP2D6 to active norfluoxetine. Its half-life is 4–6 days, that of norfluoxetine is 4–16 days, and about 60% is excreted by the kidneys (fluoxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.2). Fluoxetine is a potent CYP2D6 inhibitor and can raise the levels of drugs metabolised by this enzyme (fluoxetine SmPC, AEMPS, section 4.5). Ambroxol is metabolised in the liver by glucuronidation and hydrolysis. CYP3A4 converts about 10% of the dose, and CYP2D6 plays no role. No clinically relevant adverse interactions with other drugs have been described (ambroxol SmPC, AEMPS, sections 4.5 and 5.2).
Symptoms
The documents describe no symptoms caused by this combination. Severe skin reactions – erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis and acute generalised exanthematous pustulosis – have been reported with ambroxol (ambroxol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). Fluoxetine rarely causes serotonin syndrome, and rash and allergic reactions to it are sometimes serious (fluoxetine SmPC, AEMPS, section 4.4).
Management
According to the documents, the combination is acceptable and no dose change of fluoxetine or ambroxol is needed. Neither document names the pair, and CYP2D6, the enzyme fluoxetine inhibits, plays no role in ambroxol metabolism (fluoxetine and ambroxol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.5 and 5.2). If a progressive rash appears, sometimes with blisters or mucosal lesions, ambroxol is stopped immediately (ambroxol SmPC, AEMPS, section 4.4). In renal impairment or severe liver disease, ambroxol is used only on medical advice (ambroxol SmPC, AEMPS, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Fluoxetina, Fluoxetina Cinfa 20 mg (nº registro 63499) (2026)– AEMPS, CIMA, nº registro 63499 (Fluoxetina Cinfa 20 mg cápsulas duras EFG), revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Ambroxol, Ambroxol Cinfa 3 mg/ml jarabe (nº registro 63626), sección 4.5 (2026)– AEMPS, CIMA, nº registro 63626 (Ambroxol Cinfa 3 mg/ml jarabe EFG, Laboratorios Cinfa), revisión 10/2026, secciones 4.3, 4.4, 4.5 y 5.2